Cargando…
Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015
In Germany, routine childhood varicella vaccination was implemented in 2004 with two doses recommended since 2009. We used an immunisation information system based on countrywide health insurance claims data to analyse vaccine effectiveness (VE) and factors influencing VE. We applied proportional ha...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Centre for Disease Prevention and Control (ECDC)
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434885/ https://www.ncbi.nlm.nih.gov/pubmed/28488996 http://dx.doi.org/10.2807/1560-7917.ES.2017.22.17.30521 |
_version_ | 1783237133165658112 |
---|---|
author | Rieck, Thorsten Feig, Marcel an der Heiden, Matthias Siedler, Anette Wichmann, Ole |
author_facet | Rieck, Thorsten Feig, Marcel an der Heiden, Matthias Siedler, Anette Wichmann, Ole |
author_sort | Rieck, Thorsten |
collection | PubMed |
description | In Germany, routine childhood varicella vaccination was implemented in 2004 with two doses recommended since 2009. We used an immunisation information system based on countrywide health insurance claims data to analyse vaccine effectiveness (VE) and factors influencing VE. We applied proportional hazard models to estimate VE under various conditions and compared the risk of acquiring varicella among unvaccinated children in regions with high vs low vaccination coverage (VC). Among 1.4 million children we identified 29,404 varicella cases over a maximum follow-up of 8 years post-vaccination. One-dose VE was 81.9% (95% confidence interval (CI): 81.4–82.5), two-dose VE 94.4% (95% CI: 94.2–94.6). With dose one given 1–27 days after measles-containing vaccine (MCV), one-dose VE was 32.2% (95% CI: 10.4–48.6), two-dose VE 92.8% (95% CI: 84.8–96.6). VE was not associated with age at vaccination (11–14 vs ≥ 15 months), time since vaccination, or vaccine type. Unvaccinated children had a twofold higher risk of acquiring varicella in low VC regions. Our system generated valuable data, showing that two-dose varicella vaccination provides good protection for at least 8 years. Unvaccinated children benefit from herd effects. When the first varicella vaccine dose is given shortly after MCV, a second dose is essential. |
format | Online Article Text |
id | pubmed-5434885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | European Centre for Disease Prevention and Control (ECDC) |
record_format | MEDLINE/PubMed |
spelling | pubmed-54348852017-05-30 Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015 Rieck, Thorsten Feig, Marcel an der Heiden, Matthias Siedler, Anette Wichmann, Ole Euro Surveill Research Article In Germany, routine childhood varicella vaccination was implemented in 2004 with two doses recommended since 2009. We used an immunisation information system based on countrywide health insurance claims data to analyse vaccine effectiveness (VE) and factors influencing VE. We applied proportional hazard models to estimate VE under various conditions and compared the risk of acquiring varicella among unvaccinated children in regions with high vs low vaccination coverage (VC). Among 1.4 million children we identified 29,404 varicella cases over a maximum follow-up of 8 years post-vaccination. One-dose VE was 81.9% (95% confidence interval (CI): 81.4–82.5), two-dose VE 94.4% (95% CI: 94.2–94.6). With dose one given 1–27 days after measles-containing vaccine (MCV), one-dose VE was 32.2% (95% CI: 10.4–48.6), two-dose VE 92.8% (95% CI: 84.8–96.6). VE was not associated with age at vaccination (11–14 vs ≥ 15 months), time since vaccination, or vaccine type. Unvaccinated children had a twofold higher risk of acquiring varicella in low VC regions. Our system generated valuable data, showing that two-dose varicella vaccination provides good protection for at least 8 years. Unvaccinated children benefit from herd effects. When the first varicella vaccine dose is given shortly after MCV, a second dose is essential. European Centre for Disease Prevention and Control (ECDC) 2017-04-27 /pmc/articles/PMC5434885/ /pubmed/28488996 http://dx.doi.org/10.2807/1560-7917.ES.2017.22.17.30521 Text en This article is copyright of The Authors, 2017. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made. |
spellingShingle | Research Article Rieck, Thorsten Feig, Marcel an der Heiden, Matthias Siedler, Anette Wichmann, Ole Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015 |
title | Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015 |
title_full | Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015 |
title_fullStr | Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015 |
title_full_unstemmed | Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015 |
title_short | Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015 |
title_sort | assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, germany, 2006 to 2015 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434885/ https://www.ncbi.nlm.nih.gov/pubmed/28488996 http://dx.doi.org/10.2807/1560-7917.ES.2017.22.17.30521 |
work_keys_str_mv | AT rieckthorsten assessingvaricellavaccineeffectivenessanditsinfluencingfactorsusinghealthinsuranceclaimsdatagermany2006to2015 AT feigmarcel assessingvaricellavaccineeffectivenessanditsinfluencingfactorsusinghealthinsuranceclaimsdatagermany2006to2015 AT anderheidenmatthias assessingvaricellavaccineeffectivenessanditsinfluencingfactorsusinghealthinsuranceclaimsdatagermany2006to2015 AT siedleranette assessingvaricellavaccineeffectivenessanditsinfluencingfactorsusinghealthinsuranceclaimsdatagermany2006to2015 AT wichmannole assessingvaricellavaccineeffectivenessanditsinfluencingfactorsusinghealthinsuranceclaimsdatagermany2006to2015 |